(Q35096785)

6 August 2017

1 reference

title

Immunobiological treatments of hairy-cell leukaemia (English)

1 reference

6 August 2017

1 reference

1

Robert J Kreitman

1 reference

6 August 2017

2

Ira Pastan

1 reference

6 August 2017

1 March 2003

1 reference

Best Practice and Research: Clinical Haematology

6 August 2017

1 reference

6 August 2017

16

1 reference

6 August 2017

1

1 reference

6 August 2017

117-133

1 reference

Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study

6 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900003-3

7 January 2021

Complete remissions in hairy cell leukemia with 2-chlorodeoxyadenosine after failure with 2'-deoxycoformycin

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900003-3

7 January 2021

Diagnostic relevance of peripheral blood immunocytochemistry in hairy cell leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900003-3

7 January 2021

One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900003-3

7 January 2021

Entry of lethal doses of abrin, ricin and modeccin into the cytosol of HeLa cells

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900003-3

7 January 2021

In vitro anti-tumour activity of anti-CD80 and anti-CD86 immunotoxins containing type 1 ribosome-inactivating proteins

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900003-3

7 January 2021

Reconstitution of diphtheria toxin from two nontoxic cross-reacting mutant proteins.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900003-3

7 January 2021

Induction of apoptosis by ribosome-inactivating proteins and related immunotoxins

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900003-3

7 January 2021

Functional domains of Pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900003-3

7 January 2021

Structure of exotoxin A of Pseudomonas aeruginosa at 3.0-Angstrom resolution

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900003-3

7 January 2021

An early step in Pseudomonas exotoxin action is removal of the terminal lysine residue, which allows binding to the KDEL receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900003-3

7 January 2021

Reduction of furin-nicked Pseudomonas exotoxin A: an unfolding story

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900003-3

7 January 2021

Pseudomonas exotoxin contains a specific sequence at the carboxyl terminus that is required for cytotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900003-3

7 January 2021

Importance of the glutamate residue of KDEL in increasing the cytotoxicity of Pseudomonas exotoxin derivatives and for increased binding to the KDEL receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900003-3

7 January 2021

Domain II of Pseudomonas exotoxin A arrests the transfer of translocating nascent chains into mammalian microsomes

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900003-3

7 January 2021

The N-terminal region of the 37-kDa translocated fragment of Pseudomonas exotoxin A aborts translocation by promoting its own export after microsomal membrane insertion

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900003-3

7 January 2021

Cloning and characterization of a cellular apoptosis susceptibility gene, the human homologue to the yeast chromosome segregation gene CSE1

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900003-3

7 January 2021

Single-chain immunotoxin fusions between anti-Tac and Pseudomonas exotoxin: relative importance of the two toxin disulfide bonds.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900003-3

7 January 2021

Complete sustained response of a refractory, post-transplantation, large B-cell lymphoma to an anti-CD22 immunotoxin

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900003-3

7 January 2021

Recombinant RFB4 single-chain immunotoxin that is cytotoxic towards CD22-positive cells

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900003-3

7 January 2021

Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900003-3

7 January 2021

Cytotoxic and antitumor activity of a recombinant immunotoxin composed of disulfide-stabilized anti-Tac Fv fragment and truncated Pseudomonas exotoxin

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900003-3

7 January 2021

Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900003-3

7 January 2021

Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900003-3

7 January 2021

Hairy cell leukemia: a clinical review based on 725 cases of the Italian Cooperative Group (ICGHCL). Italian Cooperative Group for Hairy Cell Leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900003-3

7 January 2021

Interleukin-2 receptor beta-chain (p70-75) expressed on leukemic cells from adult T cell leukemia patients

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900003-3

7 January 2021

Demonstration of high-affinity interleukin-2 receptors on B-chronic lymphocytic leukemia cells: functional and structural characterization

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900003-3

7 January 2021

The IL-2/IL-2 receptor system: a current overview

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900003-3

7 January 2021

Targeting Pseudomonas exotoxin to hematologic malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900003-3

7 January 2021

Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900003-3

7 January 2021

Rituximab: mechanism of action and resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900003-3

7 January 2021

Growth inhibition of CD20-positive B lymphoma cell lines by IDEC-C2B8 anti-CD20 monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900003-3

7 January 2021

Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900003-3

7 January 2021

Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900003-3

7 January 2021

Treatment of Waldenström's macroglobulinemia with rituximab

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900003-3

7 January 2021

Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900003-3

7 January 2021

Chimeric monoclonal anti-CD20 antibody (rituximab)--an effective treatment for a patient with relapsing hairy cell leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900003-3

7 January 2021

Bone marrow remission of hairy cell leukaemia induced by rituximab (anti-CD20 monoclonal antibody) in a patient refractory to cladribine

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900003-3

7 January 2021

Efficacy of rituximab in hairy cell leukemia treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900003-3

7 January 2021

Rituximab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900003-3

7 January 2021

Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab).

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900003-3

7 January 2021

The IL-2/IL-15 receptor systems: targets for immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900003-3

7 January 2021

Peripheral blood hairy cell leukemia cells express only low affinity IL-2 receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900003-3

7 January 2021

10.1016/S1521-6926(03)00003-3

Identifiers

DOI

1 reference

6 August 2017

1 reference

PubMed ID

12670470